The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
March 16, 2021
View Complete Issue         Table of Contents 2019 
In Brief: Phesgo - A Fixed-Dose Combination for HER-2 Positive Breast Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
In Brief: Phesgo - A Fixed-Dose Combination for HER-2 Positive Breast Cancer (online only)
March 16, 2021 (Issue: 1619)
The FDA has approved a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase (Phesgo – Genentech) for use in combination with chemotherapy for neoadjuvant (preoperative) treatment of human epidermal growth factor receptor 2...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: In Brief: Phesgo - A Fixed-Dose Combination for HER-2 Positive Breast Cancer (online only)
Article code: 1619g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.